Progesterone for the Treatment of Traumatic Brain Injury III
Trial ID or NCT#
Status
Purpose
The ProTECT study will determine if intravenous (IV) progesterone (started within 4 hours of injury and given for a total of 96 hours), is more effective than placebo for treating victims of moderate to severe acute traumatic brain injury.
Official Title
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Eligibility Criteria
- * Moderate to severe brain injury (GCS 12-4)* Age 18 years or older* Blunt, closed head injury* Study drug initiated within 4 hours of injury
- * Non-Survivable injury* Bilateral dilated unresponsive pupils* Severe intoxication (ETOH \> 250 mg %)* Spinal cord injury with neurological deficits* Inability to perform activities of daily living prior to injury* Cardiopulmonary arrest* Status epilepticus on arrival* Systolic blood pressure (SBP) \< 90 on arrival or for at least 5 minutes prior to enrollment* O2 Sat \< 90 on arrival or for at least 5 minutes prior to enrollment* Prisoner or ward of state* Pregnant* Active breast or reproductive organ cancers* Known allergy to progesterone or intralipid components (egg yolk)* Known history of clotting disorder* Active thromboembolic event* Concern for inability to follow up at 6 months* Anyone listed in the Opt out registry
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Rosen Mann
6507212645
View on